XRTX
XORTX Therapeutics Inc.
Price Chart
Latest Quote
$2.21
+0.02 (+0.91%)
Current Price
| Previous Close | $2.19 |
| Open | $2.20 |
| Day High | $2.32 |
| Day Low | $2.17 |
| Volume | 12,707 |
Stock Information
| Shares Outstanding | 1.73M |
| Total Debt | $15K |
| Cash Equivalents | $250K |
| Net Income | $-2.77M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.82M |
| EPS (TTM) | $-2.45 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.84M |
| Income | $-2.77M |
| Book/sh | $0.30 |
| Cash/sh | $0.14 |
Financial Ratios
| Quick Ratio | 0.37 |
| Current Ratio | 0.86 |
| Debt/Eq | 1.17 |
Returns & Margins
| ROA | -53.82% |
| ROE | -137.44% |
Ownership
| Insider Ownership | 8.26% |
| Institutional Ownership | 2.23% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 2.76 |
| P/B | 7.39 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.34 |
| SMA50 | $2.42 |
| SMA200 | $2.94 |
| RSI | 34.68 |
| ATR | 0.2529 |
| Shares Float | 1.37M |
| Short Float | 3.54% |
| Short Ratio | 0.02 |
| Rel Volume | 0.34 |
Performance History
| Week | -3.91% |
| Month | -19.93% |
| Quarter | -5.76% |
| 6 Months | -30.28% |
| YTD | -22.46% |
| Year | -52.98% |
| 3 Years | -99.18% |
| 10 Years | -99.89% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $2.21 | 12,800 |
| 2026-06-04 | $2.25 | 10,100 |
| 2026-06-03 | $2.22 | 12,700 |
| 2026-06-02 | $2.20 | 31,000 |
| 2026-06-01 | $2.22 | 17,100 |
| 2026-05-29 | $2.30 | 28,700 |
| 2026-05-28 | $2.26 | 46,500 |
| 2026-05-27 | $2.40 | 93,800 |
| 2026-05-26 | $2.37 | 33,700 |
| 2026-05-22 | $2.18 | 22,500 |
| 2026-05-21 | $2.31 | 46,300 |
| 2026-05-20 | $2.43 | 7,700 |
| 2026-05-19 | $2.32 | 22,200 |
| 2026-05-18 | $2.60 | 32,900 |
| 2026-05-15 | $2.59 | 102,200 |
| 2026-05-14 | $2.01 | 88,800 |
| 2026-05-13 | $2.34 | 12,500 |
| 2026-05-12 | $2.43 | 57,800 |
| 2026-05-11 | $2.46 | 65,500 |
| 2026-05-08 | $2.79 | 17,300 |
| 2026-05-07 | $2.65 | 8,100 |
| 2026-05-06 | $2.76 | 11,600 |
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
đ° Latest News
XORTX Therapeutics Says Published Research Supports Company Approach to Gout Treatment
MT Newswires âĸ 2026-01-02T12:24:37ZXORTX Therapeutics Down Near 10% In US Premarket As Prices US$1.1 Million Registered Direct Offering
MT Newswires âĸ 2025-10-21T12:13:34ZMT Newswires Canada Overnight Stocks To Watch: Allied Gold; Lithium Americas; XORTX Therapeutics
MT Newswires âĸ 2025-10-21T01:00:12ZXORTX Therapeutics Jumps 45% on US$3 Million Deal to Buy Renal Program From Vectus Biosystems
MT Newswires âĸ 2025-10-17T11:44:38ZXORTX Therapeutics Edging Up In US Premarket As Initiates IND Preparation for XORLO in Gout Program
MT Newswires âĸ 2025-09-03T12:17:22Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $3,256,014 | $4,118,319 | $6,045,986 | $10,290,606 |
| Other Income Expense | $557,840 | $683,065 | $3,634,378 | $2,468,135 |
| Net Non Operating Interest Income Expense | $41,870 | $121,908 | $253,543 | $103,589 |
| Total Other Finance Cost | $-41,870 | $-121,908 | $-253,543 | $-103,589 |
| Operating Expense | $3,256,014 | $4,118,319 | $6,045,986 | $10,290,606 |
| Other Operating Expenses | $737,294 | $1,533,490 | $1,259,861 | $1,071,775 |
| General And Administrative Expense | $1,831,670 | $2,283,725 | $2,227,716 | $2,398,867 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-2,656,304 | $-3,313,346 | $-2,158,065 | $-7,718,882 |
| Net Interest Income | $41,870 | $121,908 | $253,543 | $103,589 |
| Interest Income | $41,870 | $121,908 | $253,543 | $101,367 |
| Normalized Income | $-3,214,144 | $-3,996,411 | $-5,792,443 | $-10,187,017 |
| Net Income From Continuing And Discontinued Operation | $-2,656,304 | $-3,313,346 | $-2,158,065 | $-7,718,882 |
| Net Income Common Stockholders | $-2,656,304 | $-3,313,346 | $-2,158,065 | $-7,718,882 |
| Net Income | $-2,656,304 | $-3,313,346 | $-2,158,065 | $-7,718,882 |
| Net Income Including Noncontrolling Interests | $-2,656,304 | $-3,313,346 | $-2,158,065 | $-7,718,882 |
| Net Income Continuous Operations | $-2,656,304 | $-3,313,346 | $-2,158,065 | $-7,718,882 |
| Pretax Income | $-2,656,304 | $-3,313,346 | $-2,158,065 | $-7,718,882 |
| Special Income Charges | $-1,833 | $0 | $0 | $-926,456 |
| Interest Income Non Operating | $41,870 | $121,908 | $253,543 | $101,367 |
| Operating Income | $-3,256,014 | $-4,118,319 | $-6,045,986 | $-10,290,606 |
| Depreciation Amortization Depletion Income Statement | $112,115 | $117,274 | $139,694 | $58,146 |
| Depreciation And Amortization In Income Statement | $112,115 | $117,274 | $139,694 | $58,146 |
| Amortization Of Intangibles Income Statement | $26,385 | $31,070 | $66,632 | $17,077 |
| Depreciation Income Statement | $85,730 | $86,204 | $73,062 | $41,069 |
| Per Share | ||||
| Diluted EPS | $-2.80 | $-5.75 | $-5.45 | $-23.54 |
| Basic EPS | $-2.80 | $-5.75 | $-5.45 | $-23.54 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,701,739 | $-4,684,110 | $-9,540,670 | $-12,700,595 |
| Total Unusual Items | $557,840 | $683,065 | $3,634,378 | $2,468,135 |
| Total Unusual Items Excluding Goodwill | $557,840 | $683,065 | $3,634,378 | $2,468,135 |
| Reconciled Depreciation | $112,115 | $117,274 | $139,694 | $58,146 |
| EBITDA (Bullshit earnings) | $-3,143,899 | $-4,001,045 | $-5,906,292 | $-10,232,460 |
| EBIT | $-3,256,014 | $-4,118,319 | $-6,045,986 | $-10,290,606 |
| Diluted Average Shares | $946,926 | $575,702 | $396,346 | $295,982 |
| Basic Average Shares | $946,926 | $575,702 | $396,346 | $295,982 |
| Diluted NI Availto Com Stockholders | $-2,656,304 | $-3,313,346 | $-2,158,065 | $-7,718,882 |
| Impairment Of Capital Assets | $1,833 | $0 | $0 | - |
| Gain On Sale Of Security | $559,673 | $683,065 | $3,634,378 | $3,394,591 |
| Amortization | $26,385 | $31,070 | $66,632 | $17,077 |
| Research And Development | $574,935 | $183,830 | $2,418,715 | $6,761,818 |
| Selling General And Administration | $1,831,670 | $2,283,725 | $2,227,716 | $2,398,867 |
| Other Gand A | $1,590,947 | $1,993,055 | $1,927,326 | $1,788,355 |
| Salaries And Wages | $240,723 | $290,670 | $300,390 | $610,512 |
| Restructuring And Mergern Acquisition | - | $279,031 | $0 | $926,456 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,899,092 | $3,153,429 | $4,466,772 | $6,796,977 |
| Total Assets | $2,683,530 | $4,094,527 | $5,467,964 | $12,374,026 |
| Total Non Current Assets | $1,422,432 | $1,417,829 | $1,399,181 | $1,478,458 |
| Non Current Accounts Receivable | $1,200,000 | $1,200,000 | $1,200,000 | $1,185,946 |
| Goodwill And Other Intangible Assets | $185,367 | $183,108 | $175,254 | $199,834 |
| Other Intangible Assets | $185,367 | $183,108 | $175,254 | $199,834 |
| Current Assets | $1,261,098 | $2,676,698 | $4,068,783 | $10,895,568 |
| Current Deferred Assets | $293,803 | $0 | $323,441 | $0 |
| Prepaid Assets | $22,609 | $185,412 | $236,966 | $379,620 |
| Receivables | $80,172 | $17,637 | $60,711 | $81,752 |
| Accounts Receivable | $80,172 | $17,637 | $60,711 | $81,752 |
| Cash Cash Equivalents And Short Term Investments | $864,514 | $2,473,649 | $3,447,665 | $10,434,196 |
| Cash And Cash Equivalents | $864,514 | $2,473,649 | $3,447,665 | $10,434,196 |
| Cash Equivalents | $620,492 | $2,419,963 | $3,352,666 | $6,610,979 |
| Cash Financial | $244,022 | $53,686 | $94,999 | $3,823,217 |
| Debt | ||||
| Total Debt | $37,287 | $38,785 | $11,510 | $77,599 |
| Current Debt And Capital Lease Obligation | $37,287 | $38,785 | $11,510 | $66,090 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $11,509 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $599,071 | $757,990 | $825,938 | $5,377,215 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $3,865,912 |
| Current Liabilities | $599,071 | $757,990 | $825,938 | $1,511,303 |
| Other Current Liabilities | $8,000 | $572,000 | $531,000 | - |
| Payables And Accrued Expenses | $553,784 | $147,205 | $283,428 | $1,445,213 |
| Payables | $395,539 | $84,020 | $195,814 | $1,293,807 |
| Accounts Payable | $395,539 | $84,020 | $195,814 | $1,293,807 |
| Derivative Product Liabilities | - | - | $531,000 | $3,854,403 |
| Equity | ||||
| Common Stock Equity | $2,084,459 | $3,336,537 | $4,642,026 | $6,996,811 |
| Total Equity Gross Minority Interest | $2,084,459 | $3,336,537 | $4,642,026 | $6,996,811 |
| Stockholders Equity | $2,084,459 | $3,336,537 | $4,642,026 | $6,996,811 |
| Gains Losses Not Affecting Retained Earnings | $5,725,469 | $5,986,473 | $-52,605 | $-52,605 |
| Other Equity Adjustments | $5,725,469 | $5,986,473 | $-52,605 | $-52,605 |
| Retained Earnings | $-23,824,557 | $-21,168,253 | $-17,854,907 | $-15,696,842 |
| Other Equity Interest | - | $24,746 | $5,493,003 | $6,221,904 |
| Other | ||||
| Ordinary Shares Number | $1,392,443 | $696,275 | $399,769 | $334,015 |
| Share Issued | $1,392,443 | $696,275 | $399,769 | $334,015 |
| Tangible Book Value | $1,899,092 | $3,153,429 | $4,466,772 | $6,796,977 |
| Invested Capital | $2,084,459 | $3,336,537 | $4,642,026 | $6,996,811 |
| Working Capital | $662,027 | $1,918,708 | $3,242,845 | $9,384,265 |
| Capital Lease Obligations | $37,287 | $38,785 | $11,510 | $77,599 |
| Total Capitalization | $2,084,459 | $3,336,537 | $4,642,026 | $6,996,811 |
| Capital Stock | $20,183,547 | $18,493,571 | $17,056,535 | $16,524,354 |
| Common Stock | $20,183,547 | $18,493,571 | $17,056,535 | $16,524,354 |
| Current Capital Lease Obligation | $37,287 | $38,785 | $11,510 | $66,090 |
| Current Accrued Expenses | $158,245 | $63,185 | $87,614 | $151,406 |
| Net PPE | $37,065 | $34,721 | $23,927 | $92,678 |
| Accumulated Depreciation | $-285,939 | $-200,209 | $-114,005 | $-40,943 |
| Gross PPE | $323,004 | $234,930 | $137,932 | $133,621 |
| Other Properties | $23,344 | $23,344 | $23,344 | $19,033 |
| Buildings And Improvements | $299,660 | $211,586 | $114,588 | $114,588 |
| Properties | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | - | - | $0 | $11,509 |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,823,946 | $-3,717,572 | $-6,629,528 | $-8,211,660 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,768,723 | $-3,678,648 | $-6,583,165 | $-8,165,959 |
| Cash Flow From Continuing Operating Activities | $-2,768,723 | $-3,678,648 | $-6,583,165 | $-8,165,959 |
| Operating Gains Losses | $-587,739 | $-721,896 | $-3,655,037 | $-2,466,925 |
| Investing Activities | ||||
| Capital Expenditure | $-55,223 | $-38,924 | $-46,363 | $-45,701 |
| Investing Cash Flow | $-294,953 | $-38,924 | $-46,363 | $-45,701 |
| Cash Flow From Continuing Investing Activities | $-294,953 | $-38,924 | $-46,363 | $-45,701 |
| Net Other Investing Changes | $-239,730 | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,255,535 | $3,500,542 | $0 | $4,999,640 |
| Financing Cash Flow | $1,427,544 | $2,779,509 | $-361,044 | $3,912,141 |
| Cash Flow From Continuing Financing Activities | $1,427,544 | $2,779,509 | $-361,044 | $3,912,141 |
| Net Other Financing Charges | $-738,433 | $-667,883 | $-295,251 | $-1,067,153 |
| Net Common Stock Issuance | $2,255,535 | $3,500,542 | $0 | $4,999,640 |
| Common Stock Issuance | $2,255,535 | $3,500,542 | $0 | $4,999,640 |
| Other | ||||
| Repayment Of Debt | $-89,572 | $-69,723 | $-66,089 | $-20,410 |
| End Cash Position | $864,514 | $2,473,649 | $3,447,665 | $10,434,196 |
| Beginning Cash Position | $2,473,649 | $3,447,665 | $10,434,196 | $14,869,861 |
| Effect Of Exchange Rate Changes | $26,997 | $-35,953 | $4,041 | $-136,146 |
| Changes In Cash | $-1,636,132 | $-938,063 | $-6,990,572 | $-4,299,519 |
| Proceeds From Stock Option Exercised | $14 | $16,573 | $296 | $64 |
| Net Issuance Payments Of Debt | $-89,572 | $-69,723 | $-66,089 | $-20,410 |
| Net Long Term Debt Issuance | $-89,572 | $-69,723 | $-66,089 | $-20,410 |
| Long Term Debt Payments | $-89,572 | $-69,723 | $-66,089 | $-20,410 |
| Net Intangibles Purchase And Sale | $-55,223 | $-38,924 | $-42,052 | $-26,005 |
| Purchase Of Intangibles | $-55,223 | $-38,924 | $-42,052 | $-26,005 |
| Net PPE Purchase And Sale | $0 | $0 | $-4,311 | $-19,696 |
| Purchase Of PPE | $0 | $0 | $-4,311 | $-19,696 |
| Change In Working Capital | $336,217 | $116,793 | $-1,030,741 | $1,473,762 |
| Change In Payables And Accrued Expense | $235,949 | $-134,447 | $-1,194,436 | $892,265 |
| Change In Prepaid Assets | $162,803 | $208,166 | $142,654 | $622,595 |
| Change In Receivables | $-62,535 | $43,074 | $21,041 | $-41,098 |
| Changes In Account Receivables | $-62,535 | $43,074 | $21,041 | $-41,098 |
| Stock Based Compensation | $25,155 | $122,527 | $120,984 | $487,940 |
| Asset Impairment Charge | $1,833 | $0 | $0 | $0 |
| Depreciation Amortization Depletion | $112,115 | $117,274 | $139,694 | $58,146 |
| Depreciation And Amortization | $112,115 | $117,274 | $139,694 | $58,146 |
| Amortization Cash Flow | $26,385 | $31,070 | $66,632 | $17,077 |
| Amortization Of Intangibles | $26,385 | $31,070 | $66,632 | $17,077 |
| Depreciation | $85,730 | $86,204 | $73,062 | $41,069 |
| Gain Loss On Investment Securities | $-564,000 | $-756,074 | $-3,641,403 | $-2,460,534 |
| Net Foreign Currency Exchange Gain Loss | $-23,739 | $34,178 | $-13,634 | $-6,391 |
| Net Income From Continuing Operations | $-2,656,304 | $-3,313,346 | $-2,158,065 | $-7,718,882 |
| Other Non Cash Items | - | - | - | $3,702 |
| Provisionand Write Offof Assets | - | - | - | $0 |
Fetched: 2026-05-30